Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies, Inc. and the Joseph Ahmed Foundation Announce Planned Trial for SM-88 in Ewing’s Sarcoma

Recognized sarcoma thought leader, Dr. Sant P. Chawla, will conduct the investigator-initiated Phase II studyThe Joseph Ahmed Foundation (“JAF”) will provide funding and patient support for the study...
September 18, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors

Former OraSure Technologies President and CEO and Johnson and Johnson executive to join Tyme board of directors James Biehl appointed as Chief Legal Officer of Tyme; to step down from the board of...
September 05, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer

NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), today announced that the number of currently consented or randomized subjects has exceeded the enrollment target...
August 27, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies, Inc. to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will...
July 30, 2018 07:30 ET | Source: Tyme Technologies, Inc.

Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019

NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical...
June 25, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies, Inc. Set to Join Russell 3000® Index

NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced it is set to...
June 12, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs

NEW YORK, June 12, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today release detailed patient data and...
May 30, 2018 07:30 ET | Source: Tyme Technologies, Inc.

Tyme Appoints Pharma Executive Don DeGolyer to Board of Directors

NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Tyme, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of Don DeGolyer to the...
May 17, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Announces Five Clinical Abstracts at the 2018 ASCO Annual Meeting

NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Tyme, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced the availability of...
April 09, 2018 07:00 ET | Source: Tyme Technologies, Inc.

Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018

NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical...